STP355 / Sirnaomics - LARVOL DELTA

Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit (PRNewswire) - "Sirnaomics Ltd...announced today that the Company's Executive Director and Chief Medical Officer, Dr. Michael Molyneaux, will present clinical study results of its leading product candidate STP705 for the treatment of non-melanoma skin cancers, and the Company's clinical development strategy based on its strong presence in both the U.S. and China, at the 2022 Pre-ASCO (American Society of Clinical Oncology) China Summit...on May 21, 2022 with a live Zoom Webinar....the Company intends to file INDs to initiate clinical studies in 2023 for three programs currently in later preclinical stage: STP355 for colorectal cancer and melanoma, STP369 for head and neck cancer and bladder cancer, and STP779 for cholangiocarcinoma."

Clinical data • IND • Biliary Cancer • Biliary Tract Cancer • Bladder Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Melanoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Urothelial Cancer